Gyre Therapeutics (GYRE) Receives a Buy from Noble Financial
I'm PortAI, I can summarize articles.
LeBoyer covers the Healthcare sector, focusing on stocks such as Ocugen, Eledon Pharmaceuticals, and Unicycive Therapeutics. According to TipRanks, LeBoyer has an average return of -10.6% and a 26.51% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Gyre Therapeutics with a $23.00 average price target, a 190.77% upside from current levels. In a report released on August 26, H.C. Wainwright also initiated coverage with a Buy rating on the stock with a $18.00 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments